NCT03227770 is a NA clinical trial of hemoperfusion combined with hemodialysis in End-stage Renal Disease, sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine.

Who is sponsoring NCT03227770?

NCT03227770 is sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine.

What drugs are being tested in NCT03227770?

Interventions in NCT03227770: hemoperfusion combined with hemodialysis, hemodialysis.

What condition does NCT03227770 study?

NCT03227770 studies End-stage Renal Disease.

Is NCT03227770 still recruiting?

NCT03227770 is currently completed. Last updated 29 August 2022.

Last reviewed 2022-08-29 · How we verify

NCT03227770

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Benefit of Hemodialysis Plus Hemoperfusion on Mortality

Completed NA Last updated 29 August 2022

What this trial tests

NA trial testing hemoperfusion combined with hemodialysis in End-stage Renal Disease in 1,362 participants. Completed in 31 December 2021.

Timeline

1 December 2017

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1,362
Start date	1 December 2017
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	11 locations across China

Drugs / interventions tested

hemoperfusion combined with hemodialysis
hemodialysis

Conditions studied

End-stage Renal Disease — all drugs for End-stage Renal Disease →

Sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Who can join

18 and older, any sex, with End-stage Renal Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multi-center, open-label, randomized controlled trial aims to investigate the efficacy of hemoperfusion (HP) combined with hemodialysis (HD) by evaluating all-cause mortality and cardiovascular mortality in maintenance hemodialysis patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Randomised, open-label, multicentre trial comparing haemodialysis plus haemoperfusion versus haemodialysis alone in adult patients with end-stage renal disease (HD/HP vs HD): study protocol.
Lu W, Jiang GR, HD/HP versus HD trial Group. · · 2018 · cited 8× · PMID 30056391 · DOI 10.1136/bmjopen-2018-022169
Hemoadsorption combined with hemodialysis versus hemodialysis alone on mortality in end-stage kidney disease: a randomized, open-label, multicenter trial.
Lu W, Zhang X, Guo Z, Deng Y, et al · · 2026 · PMID 41904134 · DOI 10.1038/s41467-026-71079-7
Comparison of 2-hour versus 4-hour hemoadsorption combined with hemodialysis (HAHD): an in vitro and prospective clinical evaluation.
Lu W, Jiang G. · · 2025 · PMID 41414686 · DOI 10.1080/0886022x.2025.2590229

Verify or expand the search:

Other trials of hemoperfusion combined with hemodialysis

Trials testing the same drug.

NCT05639010 — Effects of Hemodialysis Plus Hemoperfusion in Maintenance Hemodialysis Patients: A Clinical Study · NA · active not recruiting

Other recruiting trials for End-stage Renal Disease

Currently open trials in the same condition.

NCT06755372 — The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Populati · recruiting
NCT05473299 — Xeltis Hemodialysis Access Graft: aXess Pivotal Study · NA · active not recruiting
NCT05154773 — Increasing Live Donor Kidney Transplantation Through Video-based Education and Mobile Communication · NA · active not recruiting
NCT03994497 — Evaluation of the Level of Expression of CD45RC on T Lymphocytes as a Predictive Biomarker of Acute Rejection After Rena · NA · recruiting
NCT02728817 — Evaluation of the Radial Artery Deviation And Reimplantation Technique for Primary Hemodialysis Access Creation · NA · active not recruiting

Other Xinhua Hospital, Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT07506811 — Effects of Different Music Tempos on Feeding Outcomes in Preterm Infants · NA · not yet recruiting
NCT07441187 — Efficacy and Safety of Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets in Chinese Patients With Type · not yet recruiting
NCT07375602 — A Multimodal AI Prediction Model for Complications After Transcatheter Closure of Perimembranous VSD in Children · recruiting
NCT07405658 — Clinical Study on an Artificial Intelligence-Assisted Chest Radiograph Model Based on Big Data and Deep Learning for Ear · not yet recruiting
NCT07381400 — Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Stu · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03227770 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Last refreshed: 29 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03227770.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing